Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The company conducts research in the fields of pharmaceuticals and biotechnology while also operating its chain of Super Specialty Hospitals. Wockhardt Limited, incorporated in July 1999, is a global pharmaceutical and biotechnology organization providing affordable high-quality medicines for a healthier world. The Company is India's leading research-based global healthcare enterprise in fields of Pharmaceuticals, Biotechnology, and a chain of advanced Super Speciality Hospitals.
Wockhardt is headquartered in Mumbai, Maharashtra, India. Wockhardt was founded in 1967. The company has emerged as one of India's prominent pharmaceutical companies with a significant global presence spanning across multiple continents.
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals, and topicals (creams and ointments). Wockhardt Ltd (Wockhardt) is a pharmaceutical company that manufactures and markets vaccines, active pharmaceutical ingredients, formulations, and biosimilars.
The company holds a strong position in international markets. The company is amongst the top 3 Indian generic companies in the UK and the 6th largest generic supplier in the retail and hospital channels in Ireland. It is the No. 1 Methycobalamin brand in India.
The vast majority of the company's revenue is generated in Europe. The company also operates in the USA, Japan, Russia, and Rest of the world. It operates in India, the US, the UK, and emerging markets.
Its product portfolio caters to various therapeutic areas including orthopedics, dental care, dermatology, rheumatology, gynecology, pediatrics, cardiology, pain management, nephrology, neurology, and diabetes. It produces formulations, biopharmaceuticals, nutrition products,, vaccines and active pharmaceutical ingredients (APIs).
The company's research and development efforts focus on innovative solutions. The company also concentrates its research in new chemical entities (NCE), generics, abbreviated new drug applications (ANDAs), biosimilars, and novel drug delivery systems (NDDS).
The company has manufacturing plants in India, UK, Ireland, France, and US, and subsidiaries in US, UK, Ireland, and France. This global manufacturing footprint enables Wockhardt to serve diverse markets and comply with international regulatory standards.
Wockhardt has 2,394 total employees. The company's workforce is distributed across its global operations, supporting its research, manufacturing, and commercial activities.
Wockhardt has a Market Capitalization of ₹28,026 Crore as of June 2025, reflecting the company's significant market presence. Wockhardt Ltd has reported a significant improvement in its financial performance for the quarter ending March 2025, narrowing its net loss to ₹45 Crore. This represents a substantial recovery from the ₹177 Crore loss recorded in the same period last year.
Revenue for the fourth quarter of FY25 stood at ₹743 Crore, marking a 6% year-on-year increase from ₹700 Crore. Moreover, the company posted an EBITDA of ₹64 Crore, a notable turnaround from the EBITDA loss of ₹103 Crore in Q4 FY24, signaling improved cost control and performance across markets.
For the full year FY24, the revenues of WOCKHARDT stood at ₹28,810 million, which was up 3.9% compared to ₹27,730 million reported in FY23. The net loss of WOCKHARDT stood at ₹-4,720 million in FY24, which was an improvement compared to ₹-6,210 million reported in FY23.
Q4 FY25 Performance:
- Revenue: ₹743 Crore (6% YoY growth)
- Net Loss: ₹45 Crore (improved from ₹177 Crore loss in Q4 FY24)
- EBITDA: ₹64 Crore (turnaround from ₹103 Crore loss in Q4 FY24)
FY24 Annual Performance:
- Revenue: ₹28,810 million (3.9% YoY growth)
- Net Loss: ₹4,720 million (improved from ₹6,210 million loss in FY23)
Wockhardt is the first company outside the US and Europe to manufacture recombinant human insulin. This achievement demonstrates the company's technological capabilities and innovation in biotechnology.
During the COVID-19 pandemic, Wockhardt signed a contract with the Government of the United Kingdom to fill-finish the Oxford–AstraZeneca COVID-19 vaccine at the company's facility in Wrexham, Wales. The contract was extended until August 2022.
Wockhardt is focusing on a $7 billion market for its antibiotic Zaynich, with USFDA filing expected soon. Additionally, the company plans to double insulin production capacity to meet rising demand.
Search interest for Wockhardt Ltd Stock has increased by 307% in the last 30 days, reflecting an upward trend in search activity. Wockhardt Ltd's shares jumped 17% to a 52-week high of ₹1,810.45, driven by strong investor interest and positive financial results, including a 67% YoY EBITDA growth.
The company's recovery trajectory is supported by operational improvements and strategic initiatives. The positive financial results and strategic governance decisions reflect Wockhardt's efforts to enhance its operational efficiency and market positioning. The company's path to recovery is supported by its ability to improve cost management and optimize revenue streams, as seen in the latest quarterly performance.
Wockhardt represents a significant player in the global pharmaceutical industry with its diversified product portfolio, strong international presence, and commitment to innovation in biotechnology and pharmaceuticals. The company's recent financial improvements and strategic positioning make it an important entity in the Indian pharmaceutical sector.
